Trial reportESMO open2026
Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study.
Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth-related quality of life (HRQoL) has emerged as an important outcome following the introduction of tyrosine kinase inhibitors for metastatic gastrointestinal stromal tumors (GISTs). We report the HRQoL results from the randomized, placebo-controlled, phase III CHAPTER-GIST-301 study evaluating pimitespib as fourth-line therapy for metastatic GIST. PATIENTS AND
methodsHRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) v3.0 and EuroQol Five Dimensions Questionnaire-5L (EQ-5D-5L) at baseline and scheduled study visits during the blinded period. Between-group change from baseline scores were compared using a mixed model repeated measure model. The percentage of patients with a clinically meaningful deterioration (≥10 point change from baseline) in HRQoL was calculated for each EORTC QLQ-C30 item. Time to deterioration (TTD) was calculated using the Kaplan-Meier method.
resultsOverall, 86 patients were randomized to receive pimitespib (n = 58) or placebo (n = 28) in the CHAPTER-GIST-301 study. Compliance across all HRQoL questionnaires exceeded 80% by week 18. Least-squares mean changes from baseline were generally similar between pimitespib and placebo treatment groups, with the exception of diarrhea and appetite loss. Items associated with a ≥10 point difference in EORTC QLQ-C30 were diarrhea (hazard ratio 4.82, 95% confidence interval 2.17-10.71), with almost no difference in other items.
conclusionPimitespib as a new treatment option in the fourth-line setting did not negatively impact HRQoL overall, with the exception of diarrhea and appetite loss, in patients with metastatic GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.